Enovis (NYSE:ENOV) Insider Acquires $22,220.00 in Stock

Enovis Corporation (NYSE:ENOV) insider Oliver Engert bought 1,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was purchased at an average cost of $22.22 per share, for a total transaction of $22,220.00. Following the transaction, the insider owned 49,640 shares in the company, valued at $1,103,000.80. The trade was a 2.06% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Oliver Engert also recently made the following trade(s):

• On Friday, March 13th, Oliver Engert bought 1,000 shares of Enovis stock. The stock was purchased at an average cost of $23.74 per share, for a total transaction of $23,740.00.
• On Monday, March 9th, Oliver Engert bought 1,000 shares of Enovis stock. The stock was purchased at an average cost of $23.39 per share, for a total transaction of $23,390.00.
• On Friday, March 6th, Oliver Engert bought 750 shares of Enovis stock. The stock was purchased at an average cost of $24.41 per share, for a total transaction of $18,307.50.

Enovis Stock Up 3.9%

Shares of Enovis stock opened at $23.75 on Friday. The business’s 50 day simple moving average is $24.04 and its 200 day simple moving average is $24.79. Enovis Corporation has a 52-week low of $20.82 and a 52-week high of $36.82. The firm has a market cap of $1.37 billion, a PE ratio of -1.19 and a beta of 1.38. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04.

Enovis (NYSE:ENOV) last announced its earnings results on Thursday, May 7th. The company reported $0.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.82 by $0.07. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The business had revenue of $589.15 million for the quarter, compared to analyst estimates of $572.02 million. During the same quarter last year, the firm earned $0.81 EPS. Enovis’s revenue for the quarter was up 5.4% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, analysts predict that Enovis Corporation will post 3.65 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have weighed in on ENOV shares. BTIG Research restated a “buy” rating and issued a $39.00 price target on shares of Enovis in a research note on Friday, May 22nd. Wells Fargo & Company decreased their price target on Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Evercore restated an “outperform” rating and issued a $36.00 price target on shares of Enovis in a research note on Friday, May 8th. Needham & Company LLC raised their price target on Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Finally, Wall Street Zen downgraded Enovis from a “buy” rating to a “hold” rating in a research note on Saturday. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $44.50.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ENOV. Rubric Capital Management LP bought a new position in shares of Enovis during the 3rd quarter worth approximately $83,435,000. Paradigm Capital Management Inc. NY boosted its stake in Enovis by 70.2% in the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company’s stock valued at $40,420,000 after purchasing an additional 732,917 shares during the period. AQR Capital Management LLC boosted its stake in Enovis by 682.6% in the 2nd quarter. AQR Capital Management LLC now owns 498,317 shares of the company’s stock valued at $15,627,000 after purchasing an additional 434,646 shares during the period. Front Street Capital Management Inc. boosted its stake in Enovis by 106.1% in the 1st quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company’s stock valued at $16,973,000 after purchasing an additional 384,124 shares during the period. Finally, Quantinno Capital Management LP boosted its stake in Enovis by 130.8% in the 1st quarter. Quantinno Capital Management LP now owns 604,500 shares of the company’s stock valued at $13,752,000 after purchasing an additional 342,556 shares during the period. 98.45% of the stock is currently owned by institutional investors.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.